Barclays PLC Purchases 124,667 Shares of ProKidney Corp. (NASDAQ:PROK)

Barclays PLC boosted its position in shares of ProKidney Corp. (NASDAQ:PROK) by 575.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 146,321 shares of the company’s stock after buying an additional 124,667 shares during the quarter. Barclays PLC owned approximately 0.05% of ProKidney worth $281,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in ProKidney in the 3rd quarter worth $41,000. State Street Corp raised its holdings in ProKidney by 16.2% in the 3rd quarter. State Street Corp now owns 1,428,318 shares of the company’s stock worth $2,742,000 after purchasing an additional 198,836 shares in the last quarter. Suvretta Capital Management LLC increased its stake in shares of ProKidney by 32.1% in the 3rd quarter. Suvretta Capital Management LLC now owns 12,341,266 shares of the company’s stock worth $23,695,000 after acquiring an additional 3,000,000 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of ProKidney by 90.6% in the 3rd quarter. MetLife Investment Management LLC now owns 62,660 shares of the company’s stock worth $120,000 after acquiring an additional 29,789 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of ProKidney by 54.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 37,981 shares of the company’s stock worth $73,000 after acquiring an additional 13,415 shares in the last quarter. 51.59% of the stock is currently owned by institutional investors.

ProKidney Stock Up 7.5 %

Shares of NASDAQ PROK opened at $1.86 on Monday. The firm’s 50-day moving average price is $1.82 and its 200-day moving average price is $2.05. The company has a market cap of $542.49 million, a PE ratio of -3.38 and a beta of 1.32. ProKidney Corp. has a 52-week low of $1.18 and a 52-week high of $4.44.

ProKidney (NASDAQ:PROK) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). As a group, equities research analysts anticipate that ProKidney Corp. will post -0.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PROK has been the subject of several research reports. JPMorgan Chase & Co. initiated coverage on shares of ProKidney in a research note on Monday, September 30th. They issued a “neutral” rating for the company. Guggenheim began coverage on shares of ProKidney in a research report on Tuesday, September 10th. They set a “buy” rating and a $6.00 price objective on the stock. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $4.50.

ProKidney Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.